Please note that we have stopped the regular imports of Gene Expression Omnibus (GEO) data into ArrayExpress. This may not be the latest version of this experiment.
E-GEOD-30406 - The ets transcription factor ELF5 suppresses the estrogen sensitive phenotype and contributes to antiestrogen resistance in luminal breast cancer. [mouse]
Released on 13 January 2014, last updated on 20 January 2014
The ets transcription factor ELF5 specifies the differentiation of mammary progenitor cells to establish the milk-secreting lineage. ER- and poor prognosis basal breast cancers arise from this progenitor cell and these cancers express high levels of Elf5. Knockdown of ELF5 expression in basal breast cancer cell lines, or forced expression in luminal breast cancer cell lines, resulted in reduced cell proliferation. Transcript profiling and chromatin immunoprecipitation revealed that the transcriptional activity of ELF5 specified the gene expression patterns that distinguish basal from luminal breast cancer, including suppression of FOXA1, GATA3 and ER, key estrogen-action genes. Tamoxifen treatment of luminal MCF7 cells upregulated Elf5 expression and cells that acquired resistance to Tamoxifen became dependent on ELF5 for proliferation. ELF5 is a regulator of breast cancer cell proliferation, transcriptionally specifies the basal molecular subtype and is utilised by ER+ breast cancer cells to escape proliferative arrest caused by Tamoxifen. Elf5 was induced via doxycycline treated PyMT mouse tumours, in triplicate
transcription profiling by array
Mark Cowley <email@example.com>, Aaron L Statham, Adelaide Young, Alex Swarbrick, Andrea Egger, Andrew Stone, Cara J Evans, Catherine L Piggin, Christopher J Ormandy, David Gallego-Ortega, Fatima Valdes-Mora, Heather J Lee, Jason S Carroll, Julia M Gee, Liz Caldon, M C Alles, Maria Kalyuga, Mark J Cowley, Matthew J Naylor, Nicola Armstrong, Robert I Nicholson, Robert L Sutherland, Rosalind Launchbury, Stephanie L Allerdice, Susan J Clark, Tilman Brummer, Warren Kaplan, Wendy Au